Table 3.
Summary of neutralizing antibody responses to poliovirus types 1, 2, and 3 (PPI population for IPV).
| Poliovirus type | Endpoint | Timepoint | Observed response (95% CI)a |
|
|---|---|---|---|---|
| Concomitant-use group (n = 180) |
Staggered-use group (n = 187) |
|||
| 1 | GMT | Pre Dose 1 of IPV | 15.22 (12.88–17.98) | 15.66 (13.33–18.41) |
| 1 month post Dose 3 of IPV | 5,600.80 (4,898.46–6,403.85) | 5,344.24 (4,657.51–6,132.22) | ||
| % ≥ 1:8 | Pre Dose 1 of IPV | 70.0 (62.7–76.6) | 69.0 (61.8–75.5) | |
| 1 month post Dose 3 of IPV | 100.0 (98.0–100.0) | 100.0 (98.0–100.0) | ||
| % ≥ 1:64 | 1 month post Dose 3 of IPV | 100.0 (98.0–100.0) | 100.0 (98.0–100.0) | |
| 2 | GMT | Pre Dose 1 of IPV | 9.76 (8.40–11.33) | 8.86 (7.71–10.19) |
| 1 month post Dose 3 of IPV | 1059.83 (951.13–1,180.96) | 1122.43 (1,002.74–1,256.41) | ||
| % ≥ 1:8 | Pre Dose 1 of IPV | 51.1 (43.6–58.6) | 48.1 (40.8–55.5) | |
| 1 month post Dose 3 of IPV | 100.0 (98.0–100.0) | 100.0 (98.0–100.0) | ||
| % ≥ 1:64 | 1 month post Dose 3 of IPV | 100.0 (98.0–100.0) | 100.0 (98.0–100.0) | |
| 3 | GMT | Pre Dose 1 of IPV | 5.88 (5.29–6.54) | 6.49 (5.67–7.44) |
| 1 month post Dose 3 of IPV | 3405.56 (3,033.93–3,822.71) | 3261.69 (2,913.70–3,651.24) | ||
| % ≥ 1:8 | Pre Dose 1 of IPV | 26.7 (20.4–33.8) | 27.8 (21.5–34.8) | |
| 1 month post Dose 3 of IPV | 100.0 (98.0–100.0) | 100.0 (98.0–100.0) | ||
| % ≥ 1:64 | 1 month post Dose 3 of IPV | 100.0 (98.0–100.0) | 100.0 (98.0–100.0) | |
Abbreviations: CI, confidence interval; GMT, geometric mean titer; IPV, inactivated poliomyelitis vaccine. n, number of participants in per-protocol immunogenicity population for IPV.
aFor the continuous endpoints, the within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t distribution. For the dichotomous endpoints, the within-group 95% CIs are based on the exact binomial method proposed by Clopper and Pearson.